Phreesia (NYSE:PHR) Given Neutral Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their neutral rating on shares of Phreesia (NYSE:PHR) in a report released on Tuesday morning, MarketBeat reports. They currently have a $16.00 price objective on the stock, down from their prior price objective of $24.00.

PHR has been the subject of several other research reports. Robert W. Baird reissued a “neutral” rating and issued a $10.00 price objective (down from $25.00) on shares of Phreesia in a research note on Tuesday. Royal Bank Of Canada started coverage on shares of Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 target price on the stock. Citigroup reissued a “neutral” rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Phreesia in a research note on Wednesday, January 28th. Finally, Wells Fargo & Company cut their price objective on Phreesia from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, March 26th. Thirteen equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Phreesia Price Performance

PHR opened at $8.33 on Tuesday. The stock’s 50-day moving average price is $12.36 and its 200 day moving average price is $17.57. Phreesia has a 12-month low of $7.77 and a 12-month high of $32.76. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The firm has a market cap of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67.

Phreesia (NYSE:PHR) last released its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). The firm had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. Phreesia had a net margin of 0.48% and a return on equity of 3.33%. The business’s revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.11) earnings per share. As a group, sell-side analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity

In related news, SVP Amy Beth Vanduyn sold 2,202 shares of Phreesia stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $36,024.72. Following the completion of the transaction, the senior vice president owned 157,349 shares in the company, valued at $2,574,229.64. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Evan Roberts sold 6,268 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $102,544.48. Following the transaction, the insider owned 826,554 shares of the company’s stock, valued at $13,522,423.44. This trade represents a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 70,358 shares of company stock valued at $1,123,569. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Phreesia by 8.3% during the third quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock worth $134,177,000 after purchasing an additional 437,462 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Phreesia by 727.1% in the third quarter. New York State Common Retirement Fund now owns 136,856 shares of the company’s stock valued at $3,219,000 after buying an additional 120,309 shares during the last quarter. Squarepoint Ops LLC raised its stake in Phreesia by 243.6% in the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock valued at $2,872,000 after buying an additional 71,553 shares in the last quarter. Greenhouse Funds LLLP raised its stake in Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares in the last quarter. Finally, Bessemer Group Inc. lifted its holdings in Phreesia by 1,065.9% during the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock worth $13,043,000 after buying an additional 506,954 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.